Last reviewed · How we verify
Nanocoll
At a glance
| Generic name | Nanocoll |
|---|---|
| Sponsor | Anna Cruceta |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. (PHASE3)
- Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node. (NA)
- A Prospective Study Comparing Three Injection Sites to Detect Sentinel Lymph Nodes in Endometrial Cancer (NA)
- Sentinel Node Detection in Ovarian Cancer (PHASE1)
- Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer (PHASE4)
- Sentinel Node Detection in Clinical Early Stage Ovarian Cancer (NA)
- SLN in Colon Cancer Using a Multimodal Tracer (PHASE2, PHASE3)
- Axillary Sentinel Lymph Node Detection in Breast Cancers > 2 cm (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nanocoll CI brief — competitive landscape report
- Nanocoll updates RSS · CI watch RSS
- Anna Cruceta portfolio CI